As long as Novo Nordisk continues to deliver on the lofty expectations that investors have for their new GLP-1 drugs, NVO shares should continue to book nice gains. Watch this week’s video to see how we are looking to play the current setup for Novo Nordisk.
As a key part of Chuck’s Optioneering Team, I work closely with Chuck throughout the week to review various setups and we select one we feel is ripe for a favorable move. Keep an eye on your Inbox for more insight to help you navigate the markets.
Thank you,
Blane Markham
Technician
Hughes Optioneering Team
Hi Blane, this is a great service and one greatly appreciated by me.
It is great to start the week with a positive recommendation for this market. I am quite conservative, so I take your recommendations and then put them on as a debit spread. I tend to use the $5. spread and factor in a 5% to 7.5% risk factor.
Thanks for the service and I sincerely hope it continues.
Thank you for the trade.